Labopharm appoints Jeffrey M. Dayno, M.D. as Chief Medical Officer

10-May-2010 - Labopharm Inc. announced the appointment of Jeffrey M. Dayno, M.D. as Chief Medical Officer. Dr. Dayno will be responsible for leading the clinical activities for Labopharm's drug development programs, as well as overseeing the Company's medical affairs functions, including medical information ...

Labopharm completes licensing and distribution agreement with Nippon Shinyaku for once-daily tramadol in Japan

12-Apr-2010 - Labopharm Inc. announced its wholly owned subsidiary, Labopharm Europe Limited, has completed a licensing and distribution agreement for once-daily tramadol with Nippon Shinyaku Co., Ltd. of Japan Labopharm will receive an up-front payment upon signature of the agreement and is eligible to ...

Labopharm Receives FDA Approval For OLEPTRO

05-Feb-2010 - Labopharm Inc. announced the U.S. Food and Drug Administration (FDA) has approved OLEPTRO(TM) (trazodone hydrochloride) Extended Release Tablets, a novel once-daily formulation of the antidepressant trazodone, for the treatment of major depressive disorder (MDD) in adults. OLEPTRO(TM) utilizes ...

Labopharm Reports Positive Results for Phase III Study on Once-daily Trazodone

Study Achieves Primary Efficacy Endpoint and Demonstrates Improved Quality of Sleep

12-Feb-2008 - Labopharm Inc. announced that its recently completed North American Phase III clinical trial for its once-daily formulation of the antidepressant trazodone (study 04ACL3-001) achieved statistical significance for the primary efficacy endpoint (p value of 0.0183). The study also demonstrated ...